tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ANAB Stock Latest News

AnaptysBio announces Phase 2b trial results for rosnilimab in RA
The FlyAnaptysBio announces Phase 2b trial results for rosnilimab in RA
14h ago
ANAB
AnaptysBio price target raised to $80 from $55 at Stifel
PremiumThe Fly
AnaptysBio price target raised to $80 from $55 at Stifel
15h ago
ANAB
AnaptysBio price target raised to $70 from $45 at Wedbush
PremiumThe Fly
AnaptysBio price target raised to $70 from $45 at Wedbush
15d ago
ANAB
Positive Outlook for AnaptysBio: Strategic Developments and Promising Trial Results Drive Buy Rating
PremiumRatings
Positive Outlook for AnaptysBio: Strategic Developments and Promising Trial Results Drive Buy Rating
16d ago
ANAB
AnaptysBio initiated with an Overweight at Barclays
PremiumThe Fly
AnaptysBio initiated with an Overweight at Barclays
17d ago
ANAB
Trump announces lumber tariffs, Exxon Mobil to cut 2,000 jobs: Morning Buzz
PremiumThe FlyTrump announces lumber tariffs, Exxon Mobil to cut 2,000 jobs: Morning Buzz
29d ago
F
BA
Strategic Split and Promising Pipeline: AnaptysBio’s Path to Growth and Value Maximization
Premium
Ratings
Strategic Split and Promising Pipeline: AnaptysBio’s Path to Growth and Value Maximization
30d ago
ANAB
AnaptysBio price target raised to $59 from $38 at H.C. Wainwright
Premium
The Fly
AnaptysBio price target raised to $59 from $38 at H.C. Wainwright
30d ago
ANAB
AnaptysBio Announces Business Separation Plans
PremiumCompany Announcements
AnaptysBio Announces Business Separation Plans
1M ago
8K
ANAB
AnaptysBio trading resumes
PremiumThe Fly
AnaptysBio trading resumes
1M ago
ANAB
AnaptysBio announces intent to separate into two publicly traded companies
PremiumThe Fly
AnaptysBio announces intent to separate into two publicly traded companies
1M ago
ANAB
AnaptysBio trading halted, news pending
PremiumThe Fly
AnaptysBio trading halted, news pending
1M ago
ANAB
AnaptysBio jumps after Englander’s Millennium takes stake
PremiumThe FlyAnaptysBio jumps after Englander’s Millennium takes stake
1M ago
ANAB
AnaptysBio’s Promising Potential in Ulcerative Colitis Market Drives Buy Rating
Premium
Ratings
AnaptysBio’s Promising Potential in Ulcerative Colitis Market Drives Buy Rating
1M ago
ANAB
AnaptysBio falls after data abstract on Lilly’s peresolimab
Premium
The Fly
AnaptysBio falls after data abstract on Lilly’s peresolimab
1M ago
LLY
ANAB
Reaction to peresolimab update ‘seems excessive,’ says TD Cowen
PremiumThe Fly
Reaction to peresolimab update ‘seems excessive,’ says TD Cowen
1M ago
LLY
ANAB
AnaptysBio price target raised to $20 from $18 at UBS
PremiumThe Fly
AnaptysBio price target raised to $20 from $18 at UBS
3M ago
ANAB
AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating
PremiumRatings
AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating
3M ago
ANAB
AnaptysBio price target raised to $45 from $40 at Wedbush
PremiumThe Fly
AnaptysBio price target raised to $45 from $40 at Wedbush
3M ago
ANAB
Promising Clinical Trial Results and Strategic Growth Potential Drive Buy Rating for AnaptysBio
PremiumRatingsPromising Clinical Trial Results and Strategic Growth Potential Drive Buy Rating for AnaptysBio
3M ago
ANAB
AnaptysBio Reports Q2 2025 Financial Results and Updates
Premium
Company Announcements
AnaptysBio Reports Q2 2025 Financial Results and Updates
3M ago
ANAB
AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating
Premium
Ratings
AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating
3M ago
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >